Amneal Pharmaceuticals
AMRX
168 hedge funds and large institutions have $417M invested in Amneal Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 57 increasing their positions, 56 reducing their positions, and 9 closing their positions.
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
9% more funds holding
Funds holding: 154 → 168 (+14)
2% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 56
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.95% less ownership
Funds ownership: 67.46% → 66.51% (-0.95%)
13% less capital invested
Capital invested by funds: $481M → $417M (-$63.8M)
79% less call options, than puts
Call options by funds: $742K | Put options by funds: $3.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.56M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$1.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.1M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.05M |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$845K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.93M |
| 2 |
EP
Eversept Partners
New York
|
-$4.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.38M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.07M |
| 5 |
Goldman Sachs
New York
|
-$884K |
AMRX Hedge Fund Activity: Q1 2022 in Review
168 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2022, worth a combined $417M — down 13% from $481M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AMRX positions and 9 closed out — a net gain of 15 holders — while 57 added to existing stakes and 56 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.56M. The largest seller was Millennium Management, cutting an estimated $4.93M.
- 168 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2022, up from 154 in Q4 2021.
- Funds reported $417M of Amneal Pharmaceuticals stock for Q1 2022, down 13% quarter-over-quarter.
- 24 funds opened new Amneal Pharmaceuticals positions in Q1 2022 and 9 closed out, a net change of +15 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2022 was Vanguard Group, an estimated $5.56M added.
- The largest Amneal Pharmaceuticals seller in Q1 2022 was Millennium Management, an estimated $4.93M sold.
Based on aggregated 13F filings for Q1 2022.